- Khiron is a founding member of Project Twenty 21 and was the
first supplier of EU-GMP high-THC dried cannabis flower to the
study
- The findings show that medical Cannabis dramatically improves
quality of life for people with life-limiting conditions, including
Chronic Pain, Multiple Sclerosis, Tourette's Syndrome and PTSD
- Legal prescriptions allow patients to access medical cannabis
without engaging in criminality and to avoid dependency associated
with other medicines commonly prescribed for these debilitating
conditions
TORONTO, May 11, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX:
KHRNF)(Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America and Europe, applauds the publication today in the
accredited scientific journal "Psychopharmacology" of the first
findings arising from Project Twenty 21, UK's first and largest
national medical cannabis registry that was launched on
November 7, 2019 at the Royal College
of Psychiatrists in London.
Khiron Comments on the Results of Project Twenty21 – UK´s Largest
Observational Study into Medical Cannabis Products
Through Project Twenty21, eligible patients can access
affordable medical cannabis treatment, monitored by Drug Science,
UK's leading independent scientific body. The project aims to
create the UK's largest body of evidence for the effectiveness and
tolerability of medical cannabis to warrant NHS funding where the
benefits of treatment with medical cannabis are proven to outweigh
the potential risks.
The Project Twenty 21 study has now licensed prescriptions of
medical cannabis to over 900 patients who are in substantially
poorer health than the general population, and who have been unable
to manage their diagnosed conditions with commonly prescribed
medicines. The findings show that legally prescribed cannabis
provides clinically significant improvements in the quality of life
of patients living with conditions such as Chronic Pain, Multiple
Sclerosis, Tourette's Syndrome, Epilepsy and Post Traumatic Stress
Disorder (PTSD). Based on the early positive momentum of the
Project Twety21, Khiron will be launching other commercial
initiatives to reach as many people as possible in the country.
The patient data collected show that medical cannabis improves
the quality of life more than classical treatments do, for example
for neuropathic pain. According to the National Institute for
Clinical Excellence (NICE), there is little or no evidence that
commonly prescribed drugs, such as benzodiazepines or opioids, make
any difference to people's quality of life, pain or psychological
distress, but they can cause harm, including possible addiction. In
contrast, the results of Project Twenty21 clearly show a fifty
percent increase in patients' self-reported health and ability to
lead a more normal life as well as significant improvements in
patients' ability to manage debilitating secondary conditions such
as anxiety, insomnia and depression. Also, patients are now able to
avoid criminality with legal prescriptions, as many have felt
compelled to turn to illegal use to manage their conditions.
Project leader of Twenty21 Professor David Nutt from Drug Science, comments: "A lack
of clinical evidence has made it difficult for doctors to
confidently prescribe legal medical cannabis in the UK. These new
findings provide a major step forward and help to clarify the
benefit these medicines can have for thousands of seriously ill
patients."
Tejinder Virk, President of
Khiron Europe, says: "We are glad to see our strong commitment with
medical research bear its fruits with this publication. Khiron is a
true pioneer in the medical cannabis landscape in the UK, and not
just because of its products. Our biggest contribution to improve
access to medical cannabis in the UK is our education programs for
prescribing clinicians and the dissemination of our expertise with
cannabis-based therapeutics. We plan to continue our data-driven
approach with the deployment of EU-GMP cannabinoid-based medicines
based on our Colombian extracts, whose efficacy and safety are
backed by clinical data collected in our wholly-owned clinics with
over 17,000 prescriptions."
With this prescriber-oriented and patient-centered approach,
Khiron has made a reputation in the UK as a leader in medical
cannabis training thanks to its educational platform, Khiron
Academy, providing CPD-certified education to collaborative
partners such as the Medical Cannabis Clinicians Society (MCCS) and
Cellen. For further details on the results and methodology of
Project Twenty21, please see:
https://www.drugscience.org.uk/wp-content/uploads/2021/05/213_2021_5855_OnlinePDF-2.pdf
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru, Germany
and the United Kingdom, and is
positioned to commence sales in Mexico and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and United
Kingdom. The Company is led by Co-founder and Chief
Executive Officer, Alvaro Torres,
together with an experienced and diverse executive team and Board
of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Investor Contact:
Paola Ricardo
E: investors@khiron.ca
T: +1 (647) 556-5750
Media Contact:
Peter
Leis
Europe Communications Manager
E: pleis.ext@khiron.ca enavarro@khiron.ca
Khiron Europe:
Tejinder
Virk
Europe President
E: tvirk@khiron.ca
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-comments-on-the-results-of-project-twenty21--uks-largest-observational-study-into-medical-cannabis-products-301288477.html
SOURCE Khiron Life Sciences Corp.